Technical Analysis for GLTO - Galecto, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Historical GLTO trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Hot IPO Pullback | Bullish Swing Setup | -0.94% | |
| New 52 Week Closing High | Bullish | -5.88% | |
| Pocket Pivot | Bullish Swing Setup | -5.88% | |
| New 52 Week High | Strength | -5.88% | |
| Hot IPO Pullback | Bullish Swing Setup | -1.74% | |
| Narrow Range Bar | Range Contraction | -1.74% | |
| NR7 | Range Contraction | -1.74% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Fell Below 20 DMA | 2 days ago | |
| Up 3% | 3 days ago | |
| Rose Above 10 DMA | 3 days ago | |
| 20 DMA Support | 3 days ago | |
| 10 DMA Resistance | 3 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Biotechnology Cancer Clinical Medicine Biology Inflammation Non Alcoholic Fatty Liver Disease Idiopathic Pulmonary Fibrosis Fibrosis Breakthrough Therapy Lectins Mtor Myelofibrosis Galectin 3 Pulmonary Fibrosis Galecto Biotech Related Diseases
Biotechnology Cancer Clinical Medicine Biology Inflammation Non Alcoholic Fatty Liver Disease Idiopathic Pulmonary Fibrosis Fibrosis Breakthrough Therapy Lectins Mtor Myelofibrosis Galectin 3 Pulmonary Fibrosis Galecto Biotech Related Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.99 |
| 52 Week Low | 13.32 |
| Average Volume | 69,968 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 15.84 |
| 10-Day Moving Average | 16.34 |
| Average True Range | 1.20 |
| ADX | 0.0 |
| +DI | 19.60 |
| -DI | 10.80 |
| Chandelier Exit (Long, 3 ATRs ) | 14.40 |
| Chandelier Exit (Short, 3 ATRs ) | 16.91 |
| Upper Bollinger Band | 17.28 |
| Lower Bollinger Band | 14.40 |
| Percent B (%b) | 0.5 |
| BandWidth | 18.15 |
| MACD Line | 0.25 |
| MACD Signal Line | 0.25 |
| MACD Histogram | 0.0077 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.14 | ||||
| Resistance 3 (R3) | 17.25 | 16.93 | 16.93 | ||
| Resistance 2 (R2) | 16.93 | 16.60 | 16.88 | 16.85 | |
| Resistance 1 (R1) | 16.39 | 16.40 | 16.23 | 16.28 | 16.78 |
| Pivot Point | 16.07 | 16.07 | 15.99 | 16.02 | 16.07 |
| Support 1 (S1) | 15.53 | 15.74 | 15.37 | 15.42 | 14.92 |
| Support 2 (S2) | 15.21 | 15.54 | 15.16 | 14.85 | |
| Support 3 (S3) | 14.67 | 15.21 | 14.78 | ||
| Support 4 (S4) | 14.56 |
